Page 127 - 南京医科大学学报自然科学版

第43卷第9期 高钟秀，顾莹莹，唐立钧. PET显像新技术在子宫恶性肿瘤中的进展［J］.
2023年9月 南京医科大学学报（自然科学版），2023，43（9）：1301-1306 ·1305 ·

18
⁃DOTA⁃FAPI⁃04 and［ F］FDGPET/CT for the diagnosis tients with cervical cancer［J］. Nuklearmedizin Nucl
of primary and metastatic lesions in patients with various Med，2020，59（3）：241-247
types of cancer［J］. Eur J Nucl Med Mol Imaging，2020， ［25］ CARMONA R，PRITZ J，BYDDER M，et al. Fat composi⁃
47：1820-1832 tion changes in bone marrow during chemotherapy and ra⁃
［14］ VERCELLINO L，GROHEUX D，THOURY A，et al. diation therapy［J］. Int J Radiat Oncol Biol Phys，2014，90
18
Hypoxia imaging of uterine cervix carcinoma with F ⁃ （1）：155-163
FETNIM PET/CT［J］. Clin Nucl Med，2012，37（11）： ［26］ ELICIN O，CALLAWAY S，PRIOR J O，et al.［ F］FDG⁃
18
1065-1068 PET standard uptake value as a metabolic predictor of
［15］ WALKE G R，MERON S，SHENBERGER Y，et al. Cellu⁃ bone marrow response to radiation：impact on acute and
lar uptake of the ATSM⁃Cu（Ⅱ）complex under hypoxic late hematological toxicity in cervical cancer patients
conditions［J］. Chemistry Open，2021，10（4）：486-492 treated with chemoradiation therapy［J］. Int J Radiat On⁃
［16］ GRÖNROOS T，BENTZEN L，MARJAMÄKI P，et al. Com⁃ col Biol Phys，2014，90（5）：1099-1107
parison of the biodistribution of two hypoxia markers［ F］ ［27］ WYSS J C，CARMONA R，KARUNAMUNI R A，et al.
18
18
18
18
FETNIM and［ F］FMISO in an experimental mammary ［ F］Fluoro⁃2⁃deoxy⁃2⁃d⁃glucose versus 3′⁃deoxy⁃3′⁃［ F］
carcinoma［J］. Eur J Nucl Med Mol Imag，2004，31（4）： fluorothymidine for defining hematopoietically active pel⁃
513-520 vic bone marrow in gynecologic patients［J］. Radiother
［17］ BUSK M，HORSMAN M R，JAKOBSEN S，et al. Imaging Oncol，2016，118（1）：72-78
18
hypoxia in xenografted and murine tumors with F⁃fluoro⁃ ［28］ MCCANN G A，BOUTSICARIS C E，PRESTON M M，et
azomycin arabinoside：a comparative study involving mi⁃ al. Neuroendocrine carcinoma of the uterine cervix：the
-
croPET，autoradiography，PO2 polarography，and fluores⁃ role of multimodality therapy in early ⁃ stage disease［J］.
cence microscopy［J］. Int J Radiat Oncol Biol Phys，2008， Gynecol Oncol，2013，129（1）：135-139
70（4）：1202-1212 ［29］ ZIVANOVIC O，JR LEITAO M M，PARK K J，et al. Small
18
［18］ CHOI J，KIM H J，JEONG Y H，et al. The role of F⁃FDG cell neuroendocrine carcinoma of the cervix：analysis of
PET/CT in assessing therapy response in cervix cancer outcome，recurrence pattern and the impact of platinum⁃
after concurrent chemoradiation therapy［J］. Nucl Med based combination chemotherapy［J］. Gynecol Oncol，
Mol Imag，2014，48（2）：130-136 2009，112（3）：590-593
［19］ DEHDASHTI F ，GRIGSBY P W ，LEWIS J S ，et al. ［30］ISHIKAWA M，KASAMATSU T，TSUDA H，et al. Prog⁃
Assessing tumor hypoxia in cervical cancer by PET with nostic factors and optimal therapy for stages Ⅰ⁃Ⅱ neuro⁃
Cu⁃labeled diacetyl⁃bis（N4⁃methylthiosemicarbazone） endocrine carcinomas of the uterine cervix：a multi⁃center
60
［J］. J Nucl Med，2008，49（2）：201-205 retrospective study［J］. Gynecol Oncol，2018，148（1）：
［20］ GRIGSBY P W，MALYAPA R S，HIGASHIKUBO R，et 139-146
al. Comparison of molecular markers of hypoxia and imag⁃ ［31］ ANDRES D，GRACIELA L，SUSANA R，et al. Early de⁃
60
ing with Cu⁃ATSM in cancer of the uterine cervix［J］. tection of bone metastasis in small cell neuroendocrine
68
Mol Imaging Biol，2007，9（5）：278-283 carcinoma of the cervix by Ga⁃DOTATATE PET/CT ima⁃
［21］ WALLER J，ONDERDONK B，FLOOD A，et al. The clini⁃ ging［J］. Clin Nucl Med，2017，42（3）：216-217
cal utility of imaging methods used to measure hypoxia in ［32］ SHELL J，KEUTGEN X M，MILLO C，et al. Gallium
68
cervical cancer［J］. Br J Radiol，2020，93（1111）： DOTATATE scanning in symptomatic patients with nega⁃
20190640 tive anatomic imaging but suspected neuroendocrine tu⁃
［22］ BARWICK T，BENCHERIF B，MOUNTZ J M，et al. Mo⁃ mor［J］. Int J Endocr Oncol，2018，5（1）：IJE04
lecular PET and PET/CT imaging of tumour cell prolifera⁃ ［33］ VIRARKAR M，VULASALA S S，MORANI A C，et al.
18
tion using F⁃fluoro⁃L⁃thymidine：a comprehensive evalu⁃ Neuroendocrine neoplasms of the gynecologic tract［J］.
ation［J］. Nucl Med Commun，2009，30（12）：908-917 Cancers，2022，14（7）：1835
［23］ CHO L P，KIM C K，VISWANATHAN A N. Pilot study ［34］ SMITH D，STEWART C，CLARKE E M，et al. ER and PR
18
assessing F⁃fluorothymidine PET/CT in cervical and vagi⁃ expression and survival after endometrial cancer［J］.
nal cancers before and after external beam radiation［J］. Gynecol Oncol，2018，148（2）：258-266
Gynecol Oncol Rep，2015，14：34-37 ［35］ SINGH M，ZAINO R J，FILIACI V J，et al. Relationship
［24］ PAULINA C，EWA B，WITOLD C，et al. Comparison of of estrogen and progesterone receptors to clinical outcome
semiquantitative metabolic parameters of the primary tu⁃ in metastatic endometrial carcinoma：a gynecologic onco⁃
18
18
mor obtained in PET/CT with F⁃FDG and F⁃FLT in pa⁃ logy group study［J］. Gynecol Oncol，2007，106（2）：325-